Literature DB >> 22261806

Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation.

Bryan M Burt1, Andrew Bader, Daniel Winter, Scott J Rodig, Raphael Bueno, David J Sugarbaker.   

Abstract

PURPOSE: The origin and pathogenesis of malignant pleural mesothelioma (MPM) are closely aligned with inflammation. MPM tumors express interleukin-4 receptor α (IL-4Rα), the principal subunit of the IL-4 receptor. We set out to determine the biologic function and clinical relevance of IL-4Rα in human MPM. EXPERIMENTAL
DESIGN: Expression of IL-4Rα by human MPM tumors was determined by quantitative real-time PCR (n = 37) and immunohistochemistry (n = 52). Intracellular cytokine analysis of T-cell-derived IL-4 was carried out on matched tumor and blood samples from eight patients with MPM. Four human MPM cell lines were used to determine the direct effects of IL-4 on MPM tumor cells.
RESULTS: High tumor mRNA expression of IL-4Rα was an independent predictor of poor survival in patients with epithelial MPM [HR, 3.13, 95% confidence interval (CI), 1.68-7.15; P = <0.0001]. Ninety-seven percent of epithelial MPM tumors and 95% of nonepithelial MPM tumors expressed IL-4Rα protein by immunohistochemistry, and strong IL-4Rα staining correlated with worse survival in patients with epithelial histology (P = 0.04). A greater percentage of tumor-infiltrating T cells produced IL-4 compared with matched blood T cells (21% ± 7% vs. 4% ± 2%, P = 0.0002). In response to IL-4, human MPM cells showed increased STAT-6 phosphorylation and increased production of IL-6, IL-8, and VEGF, without effect on proliferation or apoptosis.
CONCLUSIONS: Tumor expression of IL-4Rα is inversely correlated with survival in patients undergoing surgical resection for epithelial MPM. Tumor-infiltrating T cells in MPMs are polarized to produce IL-4 and may provide endogenous activation signals to MPM tumor cells in situ. The IL-4/IL-4 receptor axis is a potential therapeutic target in human MPM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261806     DOI: 10.1158/1078-0432.CCR-11-1808

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

2.  Commentary: IL-4 and IL-13 receptors and signaling.

Authors:  Sarah M McCormick; Nicola M Heller
Journal:  Cytokine       Date:  2015-07-14       Impact factor: 3.861

3.  A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.

Authors:  Shuai Wang; Ke Ma; Zongwei Chen; Xiaodong Yang; Fenghao Sun; Yulin Jin; Yu Shi; Wei Jiang; Qun Wang; Cheng Zhan
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

Review 4.  The role of interleukin-6 in malignant mesothelioma.

Authors:  Siti N Abdul Rahim; Gwo Y Ho; Jermaine I G Coward
Journal:  Transl Lung Cancer Res       Date:  2015-02

5.  TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy.

Authors:  Stephen L Shiao; Brian Ruffell; David G DeNardo; Bruce A Faddegon; Catherine C Park; Lisa M Coussens
Journal:  Cancer Immunol Res       Date:  2015-02-25       Impact factor: 11.151

6.  Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.

Authors:  Kyuichi Kadota; Jonathan Villena-Vargas; Jun-Ichi Nitadori; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Ann Surg Oncol       Date:  2015-01-22       Impact factor: 5.344

7.  IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors.

Authors:  Holly A Porter; Anthony Perry; Chris Kingsley; Nhan L Tran; Achsah D Keegan
Journal:  Cancer Lett       Date:  2013-04-02       Impact factor: 8.679

Review 8.  Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Authors:  Luciano Mutti; Tobias Peikert; Bruce W S Robinson; Arnaud Scherpereel; Anne S Tsao; Marc de Perrot; Gavitt A Woodard; David M Jablons; Jacinta Wiens; Fred R Hirsch; Haining Yang; Michele Carbone; Anish Thomas; Raffit Hassan
Journal:  J Thorac Oncol       Date:  2018-09       Impact factor: 15.609

9.  Bioinformatics analysis of the structure and function of NADPH-cytochrome p450 reductase of Plasmodium vivax.

Authors:  Zhigang Fan; Kaijie Li; Lingmin Zhang; Fan Chen; Qiang Wu; Na Li; Saifeng Zhong; Guifen Lin; Guogang Yan
Journal:  Biomed Rep       Date:  2013-03-04

Review 10.  Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.

Authors:  Francesca Napoli; Angela Listì; Vanessa Zambelli; Gianluca Witel; Paolo Bironzo; Mauro Papotti; Marco Volante; Giorgio Scagliotti; Luisella Righi
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.